What Happens to CROs When Every Sponsor Wants Integrated Data?

For most of the past two decades, contract research organisations operated as service providers organised around functional silos. Bioanalytical labs ran assays. Clinical operations teams managed trials. Data management groups cleaned datasets. Regulatory teams prepared submissions. Each function delivered its output independently, and the sponsor's internal teams stitched the pieces together.

That model is breaking down.

What we are seeing across our executive search and intelligence work with CROs is a fundamental shift in what sponsors expect from their outsourcing partners. The demand is no longer for individual services delivered in parallel. It is for integrated data that flows across bioanalytical, clinical, pharmacovigilance, and real-world evidence functions without the sponsor having to reconcile it themselves.

This sounds like a technology problem. It is not. It is a leadership and organisational design problem that most CROs are not structured to solve.

What Sponsors Actually Want

The shift is easiest to understand through specific examples.

A mid-cap oncology sponsor running a Phase 2 basket trial across four tumour types wants their bioanalytical data, their clinical response data, their patient-reported outcomes, and their companion diagnostic results to be available in a single queryable dataset. Not four separate deliverables from four separate CRO functions that arrive on different timelines in different formats. One dataset. Queryable in real time. With a data model that allows their biostatisticians to run interim analyses without a six-week data reconciliation exercise.

A large pharma company with a radiopharma programme wants PK data from their bioanalytical vendor, dosimetry data from their imaging CRO, safety data from their clinical operations partner, and isotope supply chain data from their manufacturing network to be reconcilable at the patient level. They are tired of discovering data discrepancies at the point of regulatory submission that could have been caught six months earlier if the data had been integrated from the start.

A cell therapy developer wants their clinical site data, their chain-of-custody logistics data, their manufacturing batch records, and their patient outcomes data in a single system that allows end-to-end traceability from apheresis to infusion to follow-up. The current reality is that this data lives in five or six different systems operated by different vendors, and the sponsor's programme team spends a meaningful portion of their time simply reconciling records.

These are not aspirational requests. They are increasingly showing up in RFPs and partnership evaluations as threshold requirements.

Why CROs Struggle With This

The structural challenge is that most CROs were built through acquisition. The large contract research organisations assembled their service portfolios by buying specialist companies: a bioanalytical lab here, a Phase 1 unit there, a data management company, a pharmacovigilance provider, a real-world evidence consultancy. Each acquisition brought its own technology stack, its own data models, its own SOPs, and its own leadership team.

Integration was typically limited to back-office functions. Finance got consolidated. HR got consolidated. Brand identity got consolidated. But the operating systems that actually produce and manage data remained siloed because the cost of deep integration was high, the risk of disrupting ongoing client work was real, and the commercial incentive to integrate was not yet strong enough to justify the effort.

That commercial incentive now exists. Sponsors are explicitly selecting CRO partners based on their ability to deliver integrated data. The CROs that cannot do this are losing share to those that can, or are being forced to discount their services to compensate for the integration burden they are passing back to the sponsor.

The Leadership Gap

The people who can lead this transformation are rare.

What CROs need are leaders who understand clinical data standards (CDISC, SDTM, ADaM), bioanalytical data management, real-world data integration, and the technology architecture required to connect these domains. They need people who can redesign operating models, not just implement new software. They need executives who can manage the organisational politics of breaking down functional silos that have existed for a decade or more.

This profile does not map neatly to any existing CRO career path. The best bioanalytical lab directors have deep scientific expertise but limited exposure to clinical data management. The best clinical operations leaders understand trial execution but may not have worked with real-world evidence datasets. The best data management leaders understand regulatory submissions but may not have experience with the commercial data platform thinking that integrated delivery requires.

The result is a leadership market where CROs are competing for a very small pool of executives who have cross-functional data fluency combined with the operational credibility to drive organisational change. These people are being recruited aggressively. Compensation for Chief Data Officers, VP Data Strategy, and SVP Integrated Solutions roles at CROs has increased materially over the past 18 months.

The Platform Question

Underlying this organisational shift is a technology question that is often oversimplified.

Some CROs are investing in proprietary data platforms that promise to unify their service lines. Others are partnering with technology vendors who provide integration middleware. A few are pursuing the harder path of rebuilding their data architecture from the ground up around a common data model.

The technology matters, but it is not the binding constraint. The binding constraint is whether the CRO's leadership team has the vision to define what integrated delivery actually looks like for their specific service portfolio, the authority to mandate changes across business units that may resist, and the execution capability to deliver the transformation without disrupting the ongoing revenue from existing clients who are still operating under the old model.

The CROs that get this right will have a structural advantage in the next cycle of outsourcing consolidation. The ones that do not will find themselves increasingly relegated to commodity service provision, competing on price for individual functional deliverables while integrated providers capture the higher-value, longer-duration partnerships.

If You Are Hiring in CRO Leadership

The integrated data demand is reshaping the leadership profile that CROs need at the executive level. Chief Data Officers, VP Integrated Solutions, SVP Clinical Data Strategy, and related roles are becoming critical hires. If you are a CRO executive team navigating this transition, we would welcome a confidential conversation about your leadership requirements. ProGen Search runs retained executive searches for senior leadership across the contract research sector.

Byron Fitzgerald is the Founder of ProGen Search, a retained executive search and market intelligence firm serving life sciences, radiopharma, CDMO, ADC, and cell and gene therapy sectors.